2026 Special General Meeting

Proxy Card

Proxy card for the extraordinary general meeting of shareholders of Oncomatryx Biopharma, S.A., to be held in person at the company's registered office, located at Parque Tecnológico de Vizcaya, 801-B-2º, Derio (Bizkaia) (zip code 48160), with the option to attend remotely, on September 16, 2026, at 12:00 p.m. (CEST), as a single meeting.

Shareholder's full name or company name	
Number of shares	**Share numbers**

Proxy

The shareholder holding the shares indicated above hereby grants power of attorney to:

Mr./Ms. ……………………………………………… with National Identity Card (DNI) No. ………………………………………………

In the event that the person to whom the proxy is granted is not specifically named, the proxy shall be deemed granted to the Chair of the General Meeting or, in the absence thereof, to the person presiding over the General Meeting.

To provide voting instructions, please mark the corresponding box in the table below with a cross. If any of the aforementioned boxes are left unmarked, it will be understood that the specific instruction given by the principal is to vote in favor of the proposed resolutions put forward by the Board of Directors regarding matters included on the agenda.

Agenda Item	1(*)	2	3	4(*)	6	7	8(*)
In favor							
Against							
Abstain							
Blank							

(*): Items for informational purposes only; therefore, they are not subject to a vote

Unless otherwise indicated by checking the "NO" box below (in which case it will be understood that the shareholder instructs the proxy to abstain), the proxy shall extend to resolutions regarding matters not included on the agenda.

NO ☐

If this section and the following section regarding remote voting are both signed, the remote vote shall prevail and the proxy shall be void, except in the event of the shareholder's representative attending the general meeting in person or via teleconference, in which case the previous vote shall be deemed revoked.

Signature of the shareholder granting the proxy	**Signature of the proxy holder**
In ……………………………, on …, …………………, 2026	In ……………………………, on … of ………………… 2026

Proxy

Any shareholder entitled to attend may be represented by another person, even if that person is not a shareholder. The power of attorney must be granted in writing and specifically for each general meeting. Any shareholder may exercise their right to representation through the proxy form, a template of which will be available on the Company's website (**www.oncomatryx.com**) as of the date of the call for the General Shareholders' Meeting. The proxy must be completed and signed by the shareholder on the corresponding proxy card. The proxy must be accepted by the shareholder's representative; otherwise, it cannot be exercised. To this end, the representative must also sign the proxy card. The representative to whom the proxy is granted must exercise it by attending the General Shareholders' Meeting in person and presenting the proxy card at the place and on the date designated for the General Shareholders' Meeting, starting one hour before the scheduled start time of the meeting. Likewise, proxy cards may be submitted in the days leading up to the Meeting at the company's registered office, Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (zip code 48160), or may be sent by the shareholder to the following email address: **shareholders@oncomatryx.com**.

AGENDA

First. -	Reduction of the Company's share capital through the redemption of four hundred sixty-eight thousand five hundred fifty-two (468,552) treasury shares.
Second. -	Appointment, for the term provided for in the bylaws, of Fundación Bancaria Kutxa–Kutxa Banku Fundazioa as a member of the Company's board of directors.
Third. -	Setting the maximum number of board members, within the minimum and maximum limits established in the articles of incorporation.
Fourth. -	Amendment of Article 25 of the Company's articles of incorporation, effective January 1, 2027. Replacement of the CEO's variable compensation.
Fifth. -	Approval of the maximum compensation for the CEO, effective January 1, 2027.
Sixth. -	Determination of the CEO's compensation, effective January 1, 2027.
Seventh. -	Delegation of powers.
Eighth. -	Drafting, reading, and, if applicable, approval of the minutes of the meeting.